Revvity
↗Waltham, USA
Revvity is a global health science solutions company that provides technologies and services across the full spectrum of healthcare, from pharmaceutical discovery and development to clinical diagnosis. Formed in 2023 following the divestiture of PerkinElmer's Applied, Food, and Enterprise Services businesses, Revvity focuses on high-growth areas including translational multi-omics, biomarker identification, and advanced diagnostics.
The company operates through two primary segments: Life Sciences and Diagnostics. The Life Sciences segment offers reagents, instruments, and informatics software (such as the Signals platform) to support drug discovery. The Diagnostics segment provides specialized tools for immunodiagnostics, reproductive health, and newborn screening, serving clinical laboratories and hospitals worldwide.
CLASSIFICATION
Company Type:Diagnostics
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Life Sciences Tools & Diagnostics
SIZE & FINANCIALS
Employees:10000+
Revenue:$2.8B
Founded:2023
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
Investors:Vanguard Group, BlackRock, State Street Global Advisors
STOCK
Exchange:NYSE
Ticker:RVTY
Market Cap:$13.3B
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Diagnostics/Tools focus)
Modalities:Diagnostics, Gene Editing (Base Editing), Informatics, Reagents
Active Trials:5
Trial Phases:-
FDA Approvals:15
EMA Approvals:12
CORPORATE STRUCTURE
Subsidiaries:Revvity Signals Software, BioLegend, Horizon Discovery, Sirion Biotech
Key Partnerships:Sanofi (Type 1 Diabetes early detection assay), Eli Lilly (AI drug discovery models access), Genomics England (Newborn rare disease screening), Profluent (AI-enhanced base editing)
COMPETITION
Position:Leader
Competitors:Thermo Fisher Scientific, Agilent Technologies, Danaher Corporation, Illumina, Bio-Rad Laboratories
LEADERSHIP
Key Executives:
Prahlad Singh - President and CEO
Max Krakowiak - SVP and CFO
Madhuri Hegde - SVP and Chief Scientific Officer
Board Members:Alexis P. Michas (Chairman), Peter Barrett, Samuel R. Chapin, Michel Vounatsos
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Revvity. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.